GeoVax Secures Multi-Product License For ProBioGen's AGE1.CR.pIX Suspension Cell Line To Bolster MVA-Based Vaccine Development
Portfolio Pulse from Benzinga Newsdesk
GeoVax Labs, Inc. (NASDAQ:GOVX) has signed a commercial license agreement with ProBioGen for its AGE1.CR.pIX® suspension cell line. This will enhance GeoVax's manufacturing capabilities for its entire Modified Vaccinia Ankara (MVA) based vaccine portfolio. The AGE1.CR.pIX cell line enables high-yield and scalable production, leading to cost-effectiveness and increased productivity for vaccine developers. Financial terms of the agreement were not disclosed.
September 26, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The licensing agreement with ProBioGen will enhance GeoVax's vaccine manufacturing capabilities, potentially leading to increased productivity and cost-effectiveness.
The licensing agreement allows GeoVax to use ProBioGen's AGE1.CR.pIX suspension cell line, which is known for enabling high-yield and scalable production. This could lead to increased productivity and cost-effectiveness in GeoVax's vaccine manufacturing process, potentially improving the company's profitability in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100